Related references
Note: Only part of the references are listed.Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Immunopathogenesis and immunotherapy of multiple myeloma
Hideto Tamura
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S. K. Kumar et al.
LEUKEMIA (2017)
Melflufen - a peptidase-potentiated alkylating agent in clinical trials
Malin Wickstrom et al.
ONCOTARGET (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist
Shahzad Raza et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2017)
The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study
Christina Ramsenthaler et al.
BMC CANCER (2016)
Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma
Emily Rychak et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells
Arghya Ray et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Multiple myeloma: patient outcomes in real-world practice
Kwee Yong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis
Christina Ramsenthaler et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Health-related quality of life in patients with multiple myeloma - does it matter?
Ann Kristin Kvam et al.
HAEMATOLOGICA (2015)
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
Ake Berglund et al.
INVESTIGATIONAL NEW DRUGS (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Health-related quality of life in patients with multiple myeloma - does it matter?
Ann Kristin Kvam et al.
HAEMATOLOGICA (2015)
Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays
Jerry A. Katzmann et al.
CLINICAL CHEMISTRY (2015)
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma
Annamaria Brioli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)
Claudia Paba-Prada et al.
BLOOD (2014)
The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo
Sara Strese et al.
BIOCHEMICAL PHARMACOLOGY (2013)
In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Dharminder Chauhan et al.
CLINICAL CANCER RESEARCH (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan
Malin Wickstrom et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Aminopeptidase inhibition as a targeted treatment strategy in myeloma
Hannah E. Moore et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro
Malin Wickstroem et al.
INVESTIGATIONAL NEW DRUGS (2008)
Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1
J Gullbo et al.
JOURNAL OF DRUG TARGETING (2003)
Share Paper
